Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

By afschroeder • July 18, 2026

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson BD, Walter HS, Greenwald D, Calvo R, Li Y, Rule S, Furman RR. Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up. Blood Adv. 2026 Jul 28;10(14):5058-5069. doi: 10.1182/bloodadvances.2025017713. PMID: 41985004.

Tags: Hematology/Oncology, Publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Exploring Features of the Parasport Environment Associated With Quality Participation

Gee CM, Evans MB, Sinden AR, Shirazipour CH, Martin Ginis KA, Latimer-Cheung AE. Exploring Features of the Parasport Environment Associated With Quality Participation. Adapt Phys[...]

Are age and sex associated with variation in use of follow-up care and financial barriers to care in U.S. cancer survivors?

Himmelstein GE, Ganz PA. Are age and sex associated with variation in use of follow-up care and financial barriers to care in U.S. cancer survivors?[...]